Devalingam Mahalingam

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Devalingam Mahalingam is an Associate Professor of Medicine at Northwestern University Feinberg School of Medicine in the United States. His research focuses on the clinical and molecular differences in cancer treatment responses, particularly regarding immune checkpoint inhibitors and novel immunotherapeutics. Recent publications include studies on novel combinations of therapies for various solid tumors, including gastroesophageal adenocarcinoma and metastatic pancreatic cancer.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (9)

Anwaar Saeed

University of Pittsburgh

UNITED STATES

View details

Ludimila Cavalcante

Associate Professor, Director, Sarcoma Medical Oncology, Associate Director, Developmental Therapeutics

University of Virginia

UNITED STATES

View details

Susumu Shimoyama

UNITED STATES

View details

Nikolaos Trikalinos

Assistant Professor

Washington University in St. Louis

UNITED STATES

View details

Debra Richardson

Professor and Section Chief

University of Kansas Cancer Center

UNITED STATES

View details

Tarik Demir

The Ohio State University Comprehensive Cancer Center

UNITED STATES

View details

Elizabeth Davis

Vanderbilt University Medical Center

UNITED STATES

View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES

View details

Firas Wehbe

Chief Research Informatics Officer

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Devalingam Mahalingam

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden

A trial of radiolabeled antibody yttrium‐90–FF‐21101 for the treatment of advanced ovarian and other cancers

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 -Altered Advanced Solid Tumor Malignancies (NCI 10170)

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience

Collaborators (9)

Anwaar Saeed

Ludimila Cavalcante

Susumu Shimoyama

Nikolaos Trikalinos

Debra Richardson

Tarik Demir

Elizabeth Davis

Mamta Parikh

Firas Wehbe

Make your next move.